




The relative strengths and weaknesses of Vertex Pharmaceuticals INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vertex Pharmaceuticals INC MA compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Vertex Pharmaceuticals INC MA is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 2.9% points.

The company's Economic Capital Ratio, given in the ranking table, is 369%, being 124% points above the market average of 245%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 13,234,800           |
| Cost of Goods Sold                          | 1,080,300            |
| Intangible Assets                           | 1,691,600            |
| Liabilities, Current                        | 2,742,100            |
| Liabilities, Non-Current                    | 1,065,300            |
| Other Assets                                | 3,224,500            |
| Other Compr. Net Income                     | -15,100              |
| Other Expenses                              | 968,400              |
| Other Liabilities                           | 430,800              |
| Other Net Income                            | -75,000              |
| Other Revenues                              | 8,930,700            |
| Property and Equipment                      | 0                    |
| Research and Development                    | 2,540,300            |
| Selling, General and Administrative Expense | 944,700              |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 18,150,900           |
| Liabilities                 | 4,238,200            |
| Expenses                    | 5,533,700            |
| Revenues                    | 8,930,700            |
| Stockholders Equity         | 13,912,700           |
| Net Income                  | 3,322,000            |
| Comprehensive Net Income    | 3,314,450            |
| BaseVar                     | 18,471,800           |
| ECR before LimitedLiability | 301%                 |
| Economic Capital Ratio      | 369%                 |